Literature DB >> 25694474

Destruction of paranodal architecture in inflammatory neuropathy with anti-contactin-1 autoantibodies.

Kathrin Doppler1, Luise Appeltshauser1, Kai Wilhelmi1, Carmen Villmann2, Sulayman D Dib-Hajj3, Stephen G Waxman3, Mathias Mäurer4, Andreas Weishaupt1, Claudia Sommer1.   

Abstract

OBJECTIVE: Autoantibodies against paranodal proteins have been described in patients with inflammatory neuropathies, but their association with pathology of nodes of Ranvier is unclear. We describe the clinical phenotype and histopathological changes of paranodal architecture of patients with autoantibodies against contactin-1, identified from a cohort with chronic inflammatory demyelinating polyradiculoneuropathy (n=53) and Guillain-Barré syndrome (n=21).
METHODS: We used ELISA to detect autoantibodies against contactin-1. Specificity of the autoantibodies was confirmed by immunoblot assay, binding to contactin-1-transfected human embryonic kidney cells, binding to paranodes of murine teased fibres and preabsorption experiments. Paranodal pathology was investigated by immunofluorescence labelling of dermal myelinated fibres.
RESULTS: High reactivity to contactin-1 by ELISA was found in four patients with chronic inflammatory demyelinating polyradiculoneuropathy and in none of the patients with Guillain-Barré syndrome, which was confirmed by cell binding assays in all four patients. The four patients presented with a typical clinical picture, namely acute onset of disease and severe motor symptoms, with three patients manifesting action tremor. Immunofluorescence-labelling of paranodal proteins of dermal myelinated fibres revealed disruption of paranodal architecture. Semithin sections showed axonal damage but no classical signs of demyelination.
INTERPRETATION: We conclude that anti-contactin-1-related neuropathy constitutes a presumably autoantibody-mediated form of inflammatory neuropathy with distinct clinical symptoms and disruption of paranodal architecture as a pathological correlate. Anti-contactin-1-associated neuropathy does not meet morphological criteria of demyelinating neuropathy and therefore, might rather be termed a 'paranodopathy' rather than a subtype of demyelinating inflammatory neuropathy. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Entities:  

Keywords:  GUILLAIN-BARRE SYNDROME; NEUROIMMUNOLOGY; NEUROMUSCULAR; NEUROPATHY; PERIPHERAL NEUROPATHOLOGY

Mesh:

Substances:

Year:  2015        PMID: 25694474     DOI: 10.1136/jnnp-2014-309916

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  43 in total

1.  From PNS to CNS: characteristics of anti-neurofascin 186 neuropathy in 16 cases.

Authors:  Chong Xie; Ze Wang; Nan Zhao; Desheng Zhu; Xiajun Zhou; Jie Ding; Yifan Wu; Haojun Yu; Yangtai Guan
Journal:  Neurol Sci       Date:  2021-03-15       Impact factor: 3.307

Review 2.  Autoantibodies in chronic inflammatory neuropathies: diagnostic and therapeutic implications.

Authors:  Luis Querol; Jérôme Devaux; Ricard Rojas-Garcia; Isabel Illa
Journal:  Nat Rev Neurol       Date:  2017-07-14       Impact factor: 42.937

Review 3.  Immune-mediated neuropathies.

Authors:  Bernd C Kieseier; Emily K Mathey; Claudia Sommer; Hans-Peter Hartung
Journal:  Nat Rev Dis Primers       Date:  2018-10-11       Impact factor: 52.329

4.  Anti-Neurofascin-155 IgG4 antibodies prevent paranodal complex formation in vivo.

Authors:  Constance Manso; Luis Querol; Cinta Lleixà; Mallory Poncelet; Mourad Mekaouche; Jean-Michel Vallat; Isabel Illa; Jérôme J Devaux
Journal:  J Clin Invest       Date:  2019-03-14       Impact factor: 14.808

Review 5.  Distinguish CIDP with autoantibody from that without autoantibody: pathogenesis, histopathology, and clinical features.

Authors:  Lisha Tang; Qianyi Huang; Zhen Qin; Xiangqi Tang
Journal:  J Neurol       Date:  2020-04-07       Impact factor: 4.849

6.  Mechanisms of Caspr2 antibodies in autoimmune encephalitis and neuromyotonia.

Authors:  Kristina R Patterson; Josep Dalmau; Eric Lancaster
Journal:  Ann Neurol       Date:  2018-01-10       Impact factor: 10.422

7.  Neurofascin-155 IgG4 in chronic inflammatory demyelinating polyneuropathy.

Authors:  Jérôme J Devaux; Yumako Miura; Yuki Fukami; Takayuki Inoue; Constance Manso; Maya Belghazi; Kenji Sekiguchi; Norito Kokubun; Hiroo Ichikawa; Anna Hiu Yi Wong; Nobuhiro Yuki
Journal:  Neurology       Date:  2016-02-03       Impact factor: 9.910

Review 8.  Diagnostic insights into chronic-inflammatory demyelinating polyneuropathies.

Authors:  Johannes J Roggenbuck; Joseph Boucraut; Emilien Delmont; Karsten Conrad; Dirk Roggenbuck
Journal:  Ann Transl Med       Date:  2018-09

Review 9.  Association between chronic inflammatory demyelinating polyneuropathy and gastrointestinal malignancies.

Authors:  Adnan Malik; Rani Berry; Brian M Fung; James H Tabibian
Journal:  Clin J Gastroenterol       Date:  2020-11-04

Review 10.  Polyneuropathies.

Authors:  Claudia Sommer; Christian Geber; Peter Young; Raimund Forst; Frank Birklein; Benedikt Schoser
Journal:  Dtsch Arztebl Int       Date:  2018-02-09       Impact factor: 5.594

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.